This axis represents time in weeks. Dose labels along the x-axis represent individual injections. Squares represent the two initiation doses of INVEGA SUSTENNA®. Circles represent maintenance doses of INVEGA SUSTENNA®.
The injection location (deltoid muscle) and dosage strength (234 mg) of the first initiation dose is fixed and unable to be adjusted per the INVEGA SUSTENNA® Prescribing Information. Within this resource, the first initiation dose is pre-set to be represented as Day 1 on the x-axis.
The injection location (deltoid muscle) and dosage strength (156 mg) of the second initiation dose is fixed and unable to be adjusted per the INVEGA SUSTENNA® Prescribing Information. However, to help avoid a missed dose, some scenarios will allow you to shift the timing of this dose (±4 days) within the acceptable dosing window by clicking and dragging the dose label on the x-axis to the left or right.
Some scenarios will allow you to change the injection location, dosage strength, and timing of maintenance doses within the acceptable dosing window to help avoid a missed dose. To do so, either click or tap on the dose label on the x-axis to view options, or click and drag the label to the left or right to adjust the dosage timing. You may also apply the adjustments to all future doses by clicking the Apply to All Future Doses button.
Please note: Any adjustments you make to a scenario will not be saved once you view another scenario or leave this website.
This axis represents the typical paliperidone plasma concentration in nanograms per milliliter (ng/mL). Since efficacy and specific levels will vary from patient to patient, the concentration depicted is not intended to represent or imply therapeutic blood levels of paliperidone.
The light gray shaded area of the graph illustrates the estimated exposure range from use of oral INVEGA® 6-12 mg/day. The upper line represents the median paliperidone plasma concentration of oral INVEGA® 12 mg/day, and the lower line represents the median paliperidone plasma concentration of oral INVEGA® 6 mg/day.
These light orange lines illustrate the paliperidone plasma concentration of one single dose. Each dose contributes to the total concentration in the body.
This orange line indicates the cumulative paliperidone plasma concentration in the body over time. Each individual dose contributes to this curve. Changing the timing, injection location, or dosage strength of any dose will affect the total concentration curve.
Clicking on these thought bubbles will reveal additional educational information about the scenario.
The legend dropdown indicates what each graph element represents.
Along the top, there is a list of all available dosing scenarios in the INVEGA SUSTENNA® Prescribing Information.
Clicking this button will open additional background information about the dosing scenario.
This feature allows you to change the time span of the visible graph area. Some scenarios are illustrated best by a shorter or longer timeframe, so the default view will vary by scenario.
The Educational Dose Illustrator can be used to visualize how dosing affects paliperidone plasma concentrations following administration of INVEGA SUSTENNA®. This resource simulates the paliperidone plasma concentrations over time resulting from different dosing scenarios that are set forth in the INVEGA SUSTENNA® Prescribing Information.
The Educational Dose Illustrator is intended to be used as a resource to foster a better understanding and educate healthcare professionals about the dosing recommendations provided in the INVEGA SUSTENNA® Prescribing Information. It is intended for educational purposes only. It is not intended to influence prescribing practices. It is not intended to be used to determine patient prescribing dosages, treatment, or dosing strategies. Because the simulated patient blood plasma levels of INVEGA SUSTENNA® shown in the dosing scenarios are based upon aggregated pharmacokinetic information from clinical studies, the simulations may not be representative of individual patient response.
Wilson, WH. A visual guide to expected blood levels of long-acting injectable risperidone in clinical practice. J Psychiatr Pract 2004;10(6): 393-401.
Samtani MN, Gopal S, Gassmann-Mayer C, et al. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs 2011; 25(10):829-845.
The Educational Dose Illustrator is based upon the following assumptions:
These assumptions have been tested by referencing empirical data and pharmacokinetic modeling. This information is for educational purposes only and is not intended to advise prescribing decisions or dosing strategies.
The modeling data have been verified through two methods:
Acknowledging that the simplified non-compartmental superposition technique may result in slightly different predictions than the population pharmacokinetic methodology, the outcomes of the mathematical model are similar to these two sources. This information is for educational purposes only and is not intended to advise prescribing decisions or dosing strategies.
Samtani MN, Gopal S, Gassmann-Mayer C, et al. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs 2011; 25(10):829-845.
The cumulative paliperidone plasma concentration is determined by first graphing the expected plasma levels attributable to each individual dose (light orange lines). To present the cumulative paliperidone plasma concentration curve (dark orange line), plasma concentrations from all prior administrations are summed. This information is for educational purposes only and is not intended to advise prescribing decisions or dosing strategies.
Wilson, WH. A visual guide to expected blood levels of long-acting injectable risperidone in clinical practice. J Psychiatr Pract 2004;10(6): 393-401
Samtani MN, Gopal S, Gassmann-Mayer C, et al. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs 2011; 25(10):829-845.